детям и подросткам в возрасте от 9 до 15 лет и женщинам от 16 до 45 лет для предупреждения: - предраковых диспластических состояний (шейки матки, вульвы и влагалища) и рака шейки матки, вызванных онкогенными типами вируса папилломы человека (ВПЧ); - остроконечных кондилом наружных половых органов (condiloma acuminate) этиологически связанных со специфичными типами ВПЧ.

PROTEIN L1 (TYPE 11)

GARDASIL is indicated in females aged 9 through 45 years* for the prevention of cervical, vulvar, vaginal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) Types 6, 11, 16, and 18 (which are included in the vaccine). GARDASIL is indicated in males 9 through 26 years* of age for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions and infection caused by HPV types 6, 11, 16, and 18 (which are included in the vaccine). *Immunogenicity studies have been conducted to link efficacy in females and males aged 16 to 26 years to the younger populations.